Prophylaxis of Hematologic Complications With Naderin in First-Line Breast Cancer Chemotherapy (NADERIN-BC)
Medical Rehabilitation in Oncology: Prophylaxis of Hematologic and Immunologic Complications Using Naderin During First-Line Chemotherapy of Breast Cancer
The goal of this clinical trial is to learn if Naderin works to prevent low white blood cell counts in people with breast cancer receiving first-line chemotherapy. The main questions it aims to answer are:
- Does taking Naderin lower the number of people who get low white blood cell counts during chemotherapy?
- Does taking Naderin help people finish all of their chemotherapy treatments without interruptions? Researchers will compare people who receive chemotherapy with Naderin to people who receive chemotherapy alone to see if Naderin helps prevent low white blood cell counts.
Participants will:
Receive standard AC chemotherapy for breast cancer Either receive Naderin along with chemotherapy or receive chemotherapy alone Have regular blood tests to check white blood cell counts Complete all 4 chemotherapy cycles
Key finding: The study found that 14 out of 100 people who received Naderin developed low white blood cell counts, compared to 39 out of 100 people who did not receive Naderin.
研究概览
详细说明
Study Rationale Myelosuppression and related immunologic complications are common dose-limiting toxicities of cytotoxic chemotherapy and can lead to treatment delays, dose reductions, or discontinuation. This study assessed prophylactic administration of Naderin (sodium deoxyribonucleate; immunomodulatory agent) as supportive care during first-line AC chemotherapy, with the intent to mitigate hematologic toxicity and preserve chemotherapy delivery.
Study Design and Setting This was a prospective, open-label, two-group interventional study conducted at the Kazakh Scientific Research Institute of Oncology and Radiology (Almaty, Kazakhstan) in collaboration with KazNMU and the Almaty Oncology Center. Treatment allocation was non-randomized and based on consecutive enrollment, treatment availability, and participant consent.
Study Groups and Interventions Control group: standard institutional AC chemotherapy (doxorubicin + cyclophosphamide), intravenous administration, 4 planned cycles.
Intervention group: the same AC chemotherapy regimen plus Naderin administered as a prophylactic adjunct with each chemotherapy cycle (route and dosing per local institutional protocol).
Concomitant medications and supportive care (including any antiemetics, antimicrobials, or use of colony-stimulating factors) were permitted according to institutional practice and recorded.
Assessments and Follow-up
Participants underwent:
Baseline evaluation prior to chemotherapy initiation, including clinical assessment and laboratory testing.
On-treatment monitoring during each AC cycle with serial complete blood counts and structured adverse-event assessment.
End-of-treatment evaluation after completion of planned chemotherapy cycles (or earlier discontinuation), including laboratory reassessment and documentation of chemotherapy delivery (cycle completion, delays, interruptions).
Outcomes (high-level; details recorded elsewhere) The study evaluated hematologic toxicity during chemotherapy and chemotherapy delivery feasibility (ability to complete planned cycles without interruption), along with safety/tolerability of adjunctive Naderin.
Statistical Approach (high-level) The primary between-group comparison for hematologic toxicity incidence was planned using categorical testing (chi-square) with a two-sided alpha threshold of 0.05, with descriptive summaries of chemotherapy delivery metrics and adverse events.
Ethical and Oversight Considerations The study was approved by the Local Ethics Committee of KazNMU (Approval No. 15677). Written informed consent was obtained from all participants prior to enrollment. No independent data monitoring committee was used.
研究类型
注册 (实际的)
阶段
- 阶段2
- 第三阶段
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Confirmed histological diagnosis of breast cancer
- Receiving first-line AC chemotherapy (doxorubicin + cyclophosphamide)
- Age 18 years or older
- Female sex
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Adequate bone marrow function (absolute neutrophil count ≥ 1.5 × 10⁹/L, platelet count ≥ 100 × 10⁹/L)
- Adequate hepatic function (transaminases ≤ 2.5 × upper limit of normal)
- Adequate renal function (creatinine ≤ 1.5 × upper limit of normal)
- Normal cardiac function (left ventricular ejection fraction ≥ 50%)
- Willing and able to provide written informed consent
Exclusion Criteria:
- Previous chemotherapy or radiotherapy for breast cancer
- History of other malignant neoplasms (except non-melanoma skin cancer or carcinoma in situ of the cervix)
- Severe organ dysfunction (cardiac, hepatic, renal, pulmonary)
- Active infection requiring systemic therapy
- Known hypersensitivity to Naderin or any of its components
- Known hypersensitivity to doxorubicin, cyclophosphamide, or any excipients
- Pregnancy or breastfeeding
- Psychiatric or cognitive impairment that would interfere with study participation
- Participation in another interventional clinical trial within 30 days prior to enrollment
- Any condition that, in the investigator's opinion, would compromise participant safety or interfere with study objectives
学习计划
研究是如何设计的？
设计细节
- 主要用途：预防
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Naderin prophylaxis Group
Participants in this arm receive standard first-line AC chemotherapy (doxorubicin + cyclophosphamide) for 4 cycles.
In addition, participants receive Naderin (sodium deoxyribonucleate) as an adjunct prophylactic agent administered locally alongside each chemotherapy cycle to prevent hematologic and immunologic complications.
|
Naderin is an immunomodulatory agent containing sodium deoxyribonucleate.
It activates cellular and humoral immunity, stimulates reparative processes, and exhibits anti-inflammatory properties.
It is administered locally alongside each chemotherapy cycle as prophylaxis against hematologic and immunologic complications.
The agent is rapidly absorbed upon administration, distributed through lymphatic pathways to organs and tissues, and excreted primarily via the kidneys.
其他名称：
|
|
有源比较器：Chemotherapy alone Group
Participants in this arm receive standard first-line AC chemotherapy (doxorubicin + cyclophosphamide) for 4 cycles.
Participants do not receive Naderin or any other prophylactic immunomodulatory agent.
This group serves as the active comparator to evaluate the prophylactic effect of Naderin on hematologic complications.
|
Standard first-line chemotherapy regimen consisting of doxorubicin (an anthracycline antibiotic) and cyclophosphamide (an alkylating agent).
Administered intravenously for 4 cycles at standard institutional dosing.
This is the backbone chemotherapy regimen for both study arms, with the experimental arm receiving Naderin as an adjunct prophylactic agent
其他名称：
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of leukopenia during chemotherapy
大体时间：Through chemotherapy completion, up to 4 months
|
Proportion of participants who develop leukopenia (white blood cell count below the institutional lower limit of normal) during any of the 4 chemotherapy cycles.
Leukopenia is defined as a decrease in circulating white blood cells below 4.0 × 10⁹/L (or per institutional laboratory reference range)
|
Through chemotherapy completion, up to 4 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Chemotherapy completion rate
大体时间：At the end of treatment, up to 4 months
|
Proportion of participants who successfully complete all 4 planned cycles of AC chemotherapy without interruption, dose reduction, or premature discontinuation.
|
At the end of treatment, up to 4 months
|
|
Rate of chemotherapy interruption
大体时间：Through chemotherapy completion, up to 4 months
|
Proportion of participants requiring chemotherapy interruption, dose delay, or premature discontinuation due to hematologic complications or other adverse events.
|
Through chemotherapy completion, up to 4 months
|
|
Requirement for colony-stimulating factors
大体时间：Through chemotherapy completion, up to 4 months
|
Proportion of participants requiring administration of granulocyte colony-stimulating factors (G-CSF) for management of chemotherapy-induced neutropenia.
|
Through chemotherapy completion, up to 4 months
|
|
All-cause mortality
大体时间：Through study completion, up to 12 months
|
Proportion of participants who died from any cause during the study period.
|
Through study completion, up to 12 months
|
|
Quality of Life assessment
大体时间：Baseline and at end of treatment, up to 4 months
|
Change from baseline to end of chemotherapy in Global Health Status/Quality of Life (GHS/QoL) using EORTC QLQ-C30 (version 3.0).
Scores are transformed to a 0-100 scale; higher scores indicate better QoL for GHS/QoL and functioning scales (and worse symptoms for symptom scales-if reported).
|
Baseline and at end of treatment, up to 4 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- 7
- Grant of KazNMU 2012 (其他赠款/资助编号：KazNMU)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.